This is a great example of the kind of terminology debates that the ASA / ISOP
Statistics and Pharmacometrics special interest group (SxP) is trying to tackle.
As Mats and Bill point out, the common usage within our community is to say
that the percentiles (5th, 95th) are “prediction intervals”
Likewise, glad to report that Sys.unsetenv("GFORTRAN_STDOUT_UNIT") works. You
need to submit this command (preferably at the top of an R script) each time
you start R. The question remains *WHY*??? And what is different between
NONMEM-7.3 and NONMEM-7.4 (to Devin's point).
I've managed to get
(Sorry for raking up a discussion that's a month old!)
It's worth pointing people in the direction of Andrew Gelman's work on
specifying priors for between individual variance terms.
http://www.stat.columbia.edu/~gelman/research/published/taumain.pdf
Short summary: Inverse-Gamma (so by extension
Hi,
My colleagues and I are running into problems using modelling and simulation
tools which rely on Rcpp (e.g. Stan, mrgsolve, PKPDsim) alongside an existing
NONMEM installation. The problem is that we have TWO versions of compilers
installed - one for NONMEM and one from the Rtools set.
For
Dear Nele,
The EMA Scientific Advice on MCP-Mod is really worth reading here.
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/02/WC500161027.pdf
All materials from the qualification:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/doc
Also:
png("myplots%d.png")
#insert plot code here
plot(...)
dev.off()
Will create as many png files as pages in your plot. "%d" as part of the
filename is the magic here.
To change layout of graphs:
par(mfrow=c(4,2)) will give you four rows of two plots.
Mike
From: Frechen, Dr. Sebastian [mai
Andreas L,
It's perhaps easier to decide which levels of variability to use if you
consider the problems you are trying to answer:
Q1: What is the "true" value (e.g. Tmax) for this model given the data?
- Simulate without residual error.
Q2: What is the distribution of values that are consiste
Thanks Nick, for pointing us in the direction of that interesting (and
provocative) article from Sir Michael Rawlins.
QUOTE - "Sir Michael rejects the trend to grade various kinds of
clinical trials and studies on scales of merit which he says has come to
dominate the development of some aspects o
If we're simulating data for a future population (= new trial or new as
yet unstudied population) then am I right in thinking that in order to
"do the correct thing" we should really be simulating across uncertainty
in not just THETA, but also OMEGA and SIGMA? This would be my
understanding of wha
Nick,
I would argue that parametric survival models are dependent on the
"structural model" (Weibull, Exponential, Gompertz etc.) that you choose
for the hazard function and so suffer the same issues as standard PK
model building where the choice of covariates, error structures etc.
depend on the
10 matches
Mail list logo
